Long term experience of one center with targeted therapies consisting of imatinib mesylate and sunitinib malate in patients with unresectable or metastatic KIT positive gastrointestinal stromal tumors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A%230000694" target="_blank" >RIV/00209805:_____/15:#0000694 - isvavai.cz</a>

Result on the web

<a href="http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=4186&category_id=118&option=com_virtuemart&vmcchk=1&Itemid=1" target="_blank" >http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=4186&category_id=118&option=com_virtuemart&vmcchk=1&Itemid=1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/BLL_2015_042" target="_blank" >10.4149/BLL_2015_042</a>

Result language

angličtina

Original language name

Long term experience of one center with targeted therapies consisting of imatinib mesylate and sunitinib malate in patients with unresectable or metastatic KIT positive gastrointestinal stromal tumors

Original language description

A retrospective analysis of consecutive patients (183 in total, of which 105 were males and 78 females) with gastrointestinal stoma! tumour (GIST) was performed. The mean age was 61 years, median age 64 years. The most frequent localization of the tumour was stomach in 74 patients (40.4 %) and the small intestine in 46 patients (25.1 %). Two or more different synchronous or metachronous cancers occurred in 34 (18.6 %) patients with histologically confirmed GIST. Ninety-six patients were treated with imatinib mesylate in palliative setting during the course of their disease. The therapy was finished in 60 patients and 36 patients have been treated so far. The median progression-free survival reached 32.9 months in the group of 96 patients treated with imatinib. The median overall survival in the group of 96 patients treated for metastatic disease reached 77 months. Two-year and 5-year survival was 85.2 % and 63.1 %, respectively. The second-line therapy with sunitinib malate was administered in 37 patients, of which 31 finished and 6 continued in the therapy. The median progression free survival and median survival since the sunitinib therapy initiation reached 8.4 and 22.1 months, respectively (Tab. 2, Fig. 2, Ref. 16).

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Bratislava medical journal-Bratislavské lekárske listy

ISSN

0006-9248

e-ISSN

—

Volume of the periodical

116

Issue of the periodical within the volume

4

Country of publishing house

SK - SLOVAKIA

Number of pages

4

Pages from-to

218-221

UT code for WoS article

000351975100002

EID of the result in the Scopus database

2-s2.0-84940106653